Trials on MEDOX® are all independent. The trials have taken place on Universities, University Hospitals and Pharmaceutical Companies in Norway, EU, China, USA, Canada and Australia since early 2000.

MEDOX® anthocyanin supplementation may have a role in the prevention or treatment of chronic inflammatory diseases.

MEDOX® Improves LDL- and HDL-cholesterol concentrations and enhances cellular cholesterol efflux to serum. 

MEDOX® Anthocyanin supplementation improves endothelium-dependent vasodilation, serum lipid profile and decreases inflammation.

MEDOX® Significantly decreased the levels of serum high sensitivity C-reactive protein.

MEDOX® Anthocyanins protect human endothelial cells and can play an important role in the prevention of diseases associated with oxidative stress.

MEDOX® strengthens the evidence that anthocyanins may increase HDL-cholesterol levels.

MEDOX® Anthocyanin supplementation improves HDL-associated paraoxonase 1 activity and enhances cholesterol efflux capacity in subjects with hyperch...

MEDOX® Improved insulin resistance, indicators of liver injury, and clinical evolution in NAFLD patients.

MEDOX® Beneficial effects on metabolic disorders in subjects with type 2 diabetes.

MEDOX® A novel therapeutic approach in diseases involving mitochondrial dysfunction and oxidative stress.

MEDOX® vascular effects of anthocyanins.

MEDOX® Effects on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia.

MEDOX® Improved selected features of metabolic syndrome and cardiovascular risk factors.

MEDOX® Partly restores mitochondrial membrane potential.

MEDOX® Berry anthocyanins reduce proliferation of human colorectal carcinoma cells.

MEDOX® Protective activity of an anthocyanin-rich extract on hepatotoxicity.

MEDOX® Improving Cardiometabolic Risk Factors in Chinese Men and Women with Prediabetes.

MEDOX® Alzheimer disease and crossing the brain blood barrier.

MEDOX® Anthocyanin supplementation in alleviating thrombogenesis in overweight and obese population.

MEDOX® A decrease in LDL-cholesterol and increase in HDL-cholesterol concentrations were observed post 320 mg/d of ACN supplementation for 12 week...

MEDOX® Anthocyanin supplementation inhibits secretion of pro-inflammatory cytokines in overweight and obese individuals.

MEDOX® Berry anthocyanins reduce oxidative stress and inflammation. 

MEDOX® Anthocyanins in berries exhibited anti-atherogenicity and antiplatelet activities in a metabolic syndrome population.

MEDOX® Anthocyanins prevent the progression of metabolic diseases in subjects with dyslipidemia.

MEDOX® Anthocyanin supplementation at different doses improves cholesterol efflux capacity in subjects with dyslipidemia.